Organization
Viracta Therapeutics
4 clinical trials
Clinical trial
A Phase 1 Study to Investigate the Mass Balance of [14C]-Nanatinostat and to Evaluate the Relative Bioavailability of Nanatinostat in Patients With Selected Advanced CancersStatus: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Phase 1b/2 Open-Label, Dose Escalation & Expansion Study of Orally Administered VRx-3996 & Valganciclovir in Subjects With Epstein-Barr Virus-Associated Lymphoid MalignanciesStatus: Completed, Estimated PCD: 2023-04-01
Clinical trial
An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory LymphomasStatus: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
An Open-Label, Multicenter Phase 1b/2 Study of Nanatinostat and Valganciclovir in Patients With Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors and in Combination With Pembrolizumab in Patients With Recurrent/Metastatic Nasopharyngeal CarcinomaStatus: Recruiting, Estimated PCD: 2024-12-01